Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial-Reference-Cited by-同舟云学术

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

Published:2008-07 Issue:1 Volume:135 Page:100-110
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Ratziu Vlad,Giral Philippe,Jacqueminet Sophie,Charlotte Fréderic,Hartemann–Heurtier Agnès,Serfaty Lawrence,Podevin Philippe,Lacorte Jean–Marc,Bernhardt Carole,Bruckert Eric,Grimaldi André,Poynard Thierry

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference49 articles.

1. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome;Marchesini;Hepatology,2003

2. NASH: a hidden and silent fibroser finally revealed?;Ratziu;J Hepatol,2005

3. Nonalcoholic fatty liver disease: from steatosis to cirrhosis;Farrell;Hepatology,2006

4. Long-term follow-up of patients with NAFLD and elevated liver enzymes;Ekstedt;Hepatology,2006

5. The natural history of nonalcoholic fatty liver disease: a population-based cohort study;Adams;Gastroenterology,2005

Cited by 541 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Jiawei Taohe Chengqi Decoction attenuates CCl4 induced hepatic fibrosis by inhibiting HSCs activation via TGF-β1/CUGBP1 and IFN-γ/Smad7 pathway;Phytomedicine;2024-10

3. Fibroblast growth factor 21;Differentiation;2024-09

4. Evaluating Bempedoic Acid for Non-alcoholic Fatty Liver Disease: A Review of Preclinical and Clinical Research;Cureus;2024-08-18

5. PPARγ regulates PNPLA3 in adipocytes in vitro and in vivo in healthy obese patients and mice with metabolic dysfunction-associated steatohepatitis;2024-08-09